Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 3,64 € (+405,56 %). Medianen er 3,64 € (+405,56 %).
| Køb |
6 |
| Behold |
1 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
PDS Biotechnology completes private placement of $11.3 million led by Soon-Shiong
PDS Biotechnology has completed a first tranche of a private placement with gross proceeds of about $11.3 million, led by Nant Capital. The company issued common stock, prepaid warrants and accompanying warrants at prices around $0.282 and intends to use the net proceeds to repay liabilities and as working capital for clinical development. The transaction includes a contingent milestone closing under which Nant and AB Group would invest an additional $10 million and $1 million, respectively, upon filing an FDA protocol for a Phase 3 trial of PDS0301. PDS granted NantWorks a one-year right to negotiate an exclusive license to PDS0101, and Dr. Patrick Soon-Shiong and James Banaag will join the board of directors. » Mere på de.investing.com
PDS Biotechnology secures up to 22.55 million USD in private placement led by Nant Capital
PDS Biotechnology has secured up to 22.55 million USD in a private placement led by Nant Capital. The initial closing is expected to raise about 11.55 million USD through the sale of common shares or prepaid warrants at 0.2825 USD per unit; a further milestone-dependent closing of 11 million USD will be triggered upon filing an FDA protocol for a Phase 3 study of PDS0301. Nant Capital will have the right to appoint two board members, including Dr. Patrick Soon-Shiong, if it reaches an economic stake of at least 15%. The proceeds will be used to repay indebtedness, for working capital, to further develop clinical programs, and for research and administration; NantWorks also received a one-year exclusive negotiation right for a license to PDS0101. » Mere på de.investing.com
PDS Biotechnology names interim CFO after resignation of Lars Boesgaard
Lars Boesgaard submitted his resignation as CFO effective September 12, 2026; his departure is not related to any disagreements over the company’s business operations. The board appointed Janetta Trochimiuk as acting head of accounting and CEO Dr. Frank Bedu-Addo as acting chief financial officer, both positions effective September 12, 2026. Trochimiuk will retain her current base salary and remain eligible under the existing equity incentive plan; no new equity awards were granted. At the annual general meeting, shareholders approved increasing the number of authorized common shares from 150 million to 300 million. » Mere på de.investing.com
PDS Biotechnology increases authorized common shares to 300 million and elects two directors
Shareholders of PDS Biotechnology approved an amendment to increase the authorized common shares from 150 million to 300 million; the vote was 19,904,111 in favor and 11,545,436 against. At the annual meeting, where roughly 56.6% of outstanding shares were represented, Kamil Ali-Jackson and Ilian Iliev were elected as Class B directors. Shareholders also ratified KPMG US LLP as the independent registered public accounting firm for fiscal 2026 and approved a non-binding, advisory say-on-pay vote. » Mere på de.investing.com
PDS Biotechnology surpasses Q1 2026 EPS forecast after significant cost cuts
PDS Biotechnology reported Q1 2026 EPS of -$0.13, beating the analyst expectation of -$0.15. The company cut R&D expenses by 39.7% and reduced the net loss to $7.3 million, while cash and cash equivalents stood at $21.7 million. Strategic adjustments to the VERSATILE‑003 study are intended to accelerate the approval process; despite improvements, losses are still expected in coming quarters. The stock rose 6.36% in premarket trading on positive investor reaction. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -6,73 mio. | 12,36 % |
| EBITDA | -5,21 mio. | 22,22 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 44,42 mio. € |
Antal aktier | 55,82 mio. |
Højeste/laveste i 52 uger | 1,63 € - 0,18 € |
| Udbytte | Nej |
Beta | 1,45 |
P/E (PE Ratio) | -1,56 |
PEG (PEG Ratio) | -0,04 |
K/I (PB Ratio) | 0,00 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
PDS Biotechnology Corporation, et klinisk fase biofarmaceutisk selskab, fokuserer på udvikling af multifunktionelle kræftimmunterapier. Dets vigtigste produktkandidat er PDS0101 (HPV16), som er i fase II-klinisk forsøg og tilbyder en førstelinjebehandling for tilbagevendende/metastatisk hoved-halskræft, humant papillomavirus-associerede maligniteter og livmoderhalskræft. Selskabet udvikler også forskellige produktkandidater, som er i prækliniske forsøg, herunder PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) til behandling af prostata- og brystkræft; PDS0103 (MUC-1) til ovarie-, tyktarms-, lunge- og brystkræft; og PDS0104, som omfatter Tyrosinase-related protein 2 til behandling af melanom. Derudover udvikler det PDS0201 til behandling af tuberkulose; PDS0202, en influenzavaccinekandidat; og PDS0203, en vaccine til forebyggelse af COVID-19. Selskabet har licens- og samarbejdsaftaler med National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services og MSD International GmbH. PDS Biotechnology Corporation blev grundlagt i 2005 og har hjemsted i Florham Park, New Jersey.
| Navn | PDS BIOTECHNOLOGY CORP. |
| CEO | Frank K. Bedu-Addo |
| Hjemsted | Princeton,
nj USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 30.09.2015 |
| Medarbejdere | 21 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | PDSB |
Frankfurt | EU6.F |
Düsseldorf | EU6.DU |
München | EU6.MU |